WORKSHOP 4 of the EUROPLAN National Conferences

Theme 4: Centres of Expertise and European Reference Networks for Rare Diseases

Table of Contents

Annex (*separate document*) – Overall outcomes from Final Report & Synopsis of detailed outcomes of 2010 EUROPLAN National Conferences on Governance and Monitoring of a NP

A. How to read and use these Content Guidelines

The EUROPLAN Content Guidelines cover 6 main Themes. For each Theme, these Content Guidelines cover all the core topics to be addressed in the Workshop dedicated to that Theme. These Guidelines include:

1st column – RESOURCES	**2nd column - TOPICS FOR DISCUSSION**
This column includes the background documents and relevant material that should be referred to in preparation for the discussion. They mainly include: • Specific articles of the EU Council Recommendation on an action in the field of rare diseases; • Specific recommendations from the "EUROPLAN Recommendations"; • Specific items from the Commission Communication on Rare Diseases: Europe's Challenges; • Extracts from the Synthesis Report of the 15 EUROPLAN National Conferences held in 2010; • EUCERD Recommendations on Quality Criteria for Centres of Expertise in Member States; • Specific articles from the EU Directive on Cross Border Health Care. Upcoming EUCERD Recommendations will be incorporated when adopted, including: • EUCERD Recommendations on European Reference Networks (due for adoption in 2013); • EUCERD Recommendations on Rare Disease Patient Registries (due for adoption in 2013). **NB: Full documents of the sources referenced above can be found in Section C**	**The topics for discussion are questions formulated to stimulate the discussion within the Workshop**. The conference organisers, with the help of their Advisor, will **select those questions that are relevant for the discussion in their countries**. As such, **not all listed questions need to be addressed in a mandatory way**. They rather represent a "menu" from which to pick the questions that address the most relevant topics in the country, having considered the level of advancement of the national policy on rare diseases in the country.

B. Guidelines for discussion

RESOURCES	TOPICS for DISCUSSION
B.1 Designation and evaluation of CE (Centres of Expertise)	
Council Recommendation on RD 11. Identify appropriate centres of expertise throughout their national territory by the end of 2013, and consider supporting their creation. **EUROPLAN recommendations** R 4.1 Well defined mechanisms of designation of centres of expertise are established and their quality is assured, efficiency and long term sustainability. *See also page 43 of EUROPLAN Recommendations for case studies of Identification and Designation of Centres of Expertise in DK, FR, IT, SP, UK; and page 44 for case studies of evaluation of CEs in DK, FR, SP, UK.* R 4.4 A national directory of Centres of expertise is compiled and made publicly available. **EUCERD Recommendations for Quality Criteria for CEs** **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 16. A national directory of formally designated CEs is compiled and made publicly available, including on the Orphanet portal. **"Criteria for designation of CEs for RD in MS" (17-32)** 17. Capacity to produce and adhere to good practice guidelines for diagnosis and care. 18. Quality management in place to assure quality of care, including National and European legal provisions, and participation in internal and external quality schemes when applicable. 19. Capacity to propose quality of care indicators in their area and implement outcome measures including patient satisfaction. 20. High level of expertise and experience documented, for instance, by the annual volume of referrals and second opinions, and through peer-reviewed publications, grants, positions, teaching and training activities. 21. Appropriate capacity to manage RD patients and provide expert advice.	**Mapping of CEs** • Starting from the recognition that expertise on RDs exist in all countries, (see Final Report of EUROPLAN I conferences, Area 4) what is the level of knowledge of the existing expertise in the country? Is there a mapping of structures providing expertise on rare diseases? • Have their different roles and competences been acknowledged? **Designation criteria** • Are designation criteria being defined? If not, is there a procedure in place to define and approve such designation criteria? • Are the designation criteria such to adapt to the characteristics of the disease or group of diseases covered by each CE? • What sort of quality management is ensured within CEs throughout the national territory? • Please compare the designation criteria adopted in your country with the EUCERD Recommendations on Quality Criteria for CEs (*see left column*). What recommended criteria are missing? Which ones could be incorporated? **Designation process of CEs** • At what stage of development is the process of designation of CEs in your country? • What designation process is in place or will be put in place to designate CEs? • Considering the mapping of existing resources, how to better rationalise the existing resource instead of creating new ones and new centres, while compliance with agreed quality criteria and standards? • Are patient organisations involved in the designation of CEs? *(See for the*

22. Contribution to state-of-the-art research. 23. Capacity to participate in data collection for clinical research and public health purposes. 24. Capacity to participate in clinical trials, if applicable. 25. Demonstration of a multi-disciplinary approach, when appropriate, integrating medical, paramedical, psychological and social needs (e.g. RD board). 26. Organisation of collaborations to assure the continuity of care between childhood, adolescence and adulthood, if relevant. 27. Organisation of collaborations to assure the continuity of care between all stages of the disease. 28. Links and collaboration with other CE at national, European and international level. 29. Links and collaboration with patient organisations where they exist. 30. Appropriate arrangements for referrals within individual Member States and from/to other EU countries if applicable. 31. Appropriate arrangements to improve the delivery of care and especially to shorten the time taken to reach a diagnosis. 32. Consideration of E-Health solutions (e.g. shared case management systems, expert systems for tele-expertise and shared repository of cases). **"Process for designating and evaluating CEs for RD in MS" (33-40)** 33. MS take action concerning the establishment and designation and evaluation of CEs and facilitate access to these centres. 34. MS establish a procedure to define and approve designation criteria and a transparent designation and evaluation process. 35. The designation criteria defined by MS are adapted to the characteristics of the disease or group of diseases covered by the CE. 36. CEs may not fulfill some of the designation criteria defined by the MS as long as the absence of fulfillment of those criteria does not impact on the quality of care and as long as CEs have a strategy in place to attain designation criteria in a defined time period. 37. The designation process at MS level ensures that the designated CEs have the capacity, and the resources to fulfill the obligations of designation. 38. The designation of a CE is valid for a defined period of time. 39. CE are re-evaluated on a regular basis through a process incorporated into the designation process at MS level. 40. The designating authority at MS level may decide to withdraw the designation of a centre of expertise if one or more of the conditions that formed the basis for	*example the French "Comité national consultatif de labellisation" (CNCL), a national advisor committee, where patient representatives are involved with experts, relevant authorities and members of learned societies.* • Is there a national directory of CEs? Is it publicly accessible? **Evaluation of CEs** • Are CEs evaluated on a regular basis? Is this evaluation process incorporated into the designation process at national level? • Which "quality of care" indicators are adopted and what outcome measures are considered? Do they include patient satisfaction as a minimum? • What actors are involved in the evaluation process? Specifically, are patients and patient organisations involved in the evaluation process of CEs? **Information on available expertise and CEs** • How expertise available in the country and CEs are made known and accessible to patients? • Is there a national directory of formally designated CEs made publicly available, including on the Orphanet portal? (see EUCERD Recommendation n°16 and EUROPLAN Recommendation R 4.4) • What other sources of information are used apart from Orphanet?

designation is no longer satisfied, or if there is no longer a need to maintain the national service.	
B.2 Scope and functioning of CEs	
Council Recommendation on RD 14. Support the use of information and communication technologies such as telemedicine where it is necessary to ensure distant access to the specific healthcare needed. 15. Include, in their plans or strategies, the necessary conditions for the diffusion and mobility of expertise and knowledge in order to facilitate the treatment of patients in their proximity. **EUROPLAN recommendations** R 4.5 Travelling of biological samples, radiologic images, other diagnostic materials, and e-tools for tele-expertise are promoted. **EUCERD Recommendations on Quality Criteria for CEs** **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)" (1-14)** 1. CEs tackle diseases or conditions requiring specific care due to the difficulty in establishing a diagnosis, to prevent complications and/or to set up treatments. 2. CEs are expert structures for the management and care of RD patients in a defined catchment area, preferably national, and at international level if necessary. 3. The combined scope of all CEs within a MS covers all RD patients' needs, even if they cannot provide a full range of services with the same level of expertise for each RD. 7. CEs collaborate with patient organisations to bring in the patients' perspective. 11. CEs respond to the needs of patients from different cultures and ethnic groups (i.e. have cultural sensitivity). 14. The scope of diseases covered by each CE, or by a CE at national level, will vary depending on the size of the country and the structure of the national health care system. 15. CEs liaise with other CEs at National and European level when relevant. **"Criteria for designation of CEs for RD in MS"**	**Definition** Analyse the (explicit or implicit) **definition of CEs** in your country and compare with the EUCERD Recommendation on Quality Criteria for CEs: "*CEs are expert structures for the management and care of RD patients in a defined catchment area, preferably national, and at international level if necessary. CEs tackle diseases or conditions requiring specific care due to the difficulty in establishing a diagnosis, to prevent complications and/or to set up treatments.*" **Scope** • What **scope of CEs** in your country? Does the combined scope of all CEs within your country cover all RD patients' needs? How to ensure that all patients living with a RD have access to the appropriate CE in your country or abroad? • Especially in smaller countries, where the existing expertise cannot possibly cover all RDs, do CEs rely on networks of experts? • What distribution of competences between the national and the regional level? **Involvement of patients and patient organisations** • What type of collaboration with patients and their organisations is established? • How to ensure that patient representatives are closely involved in the management and decision-making processes of CEs in a systematic manner? • In particular, are patients involved in those areas where they can be specific added value e.g. social counselling? (See EUROPLAN I Final Report, Area 4) • What solutions are envisaged when a patient organisation does not exist for the specific disease(s) covered in the scope of a specific CE? How do individual patients are heard and involved? **High level of expertise and mobility of expertise**

20. High level of expertise and experience documented, for instance, by the annual volume of referrals and second opinions, and through peer-reviewed publications, grants, positions, teaching and training activities. 21. Appropriate capacity to manage RD patients and provide expert advice. 29. Links and collaboration with patient organisations where they exist. 32. Consideration of E-Health solutions (e.g. shared case management systems, expert systems for tele-expertise and shared repository of cases).	• How is the level of expertise available in CEs measured and accounted for (see examples in EUCERD Recommendation n° 20)? • How do CEs share expertise amongst themselves and through networks of expertise in the country and abroad? • What solutions are provided in order to support the mobility of expertise - a) amongst CEs; - b) CEs and diagnostic laboratories; - c) providers of care at local level? • What is the role of e-health solutions? What concrete solutions exist and/or could be put in place e.g. shared case management systems, expert systems for tele-expertise, shared repository of cases, etc. (see EUCERD Recommendation n° 32)? • What solutions are or could be prescribed "to bring highly specialised expertise on rare diseases to ordinary clinics and practices, such as a second opinion from a centre of excellence"? (see EUROPLAN Recommendation, par. 63 page 46)
B.3 Multidisciplinarity, healthcare pathways & continuity of care	
Council Recommendation on RD 13. Organise healthcare pathways for patients suffering from rare diseases through the establishment of cooperation with relevant experts and exchange of professionals and expertise within the country or from abroad when necessary. 15. Include, in their plans or strategies, the necessary conditions for the diffusion and mobility of expertise and knowledge in order to facilitate the treatment of patients in their proximity. 16. Encourage centres of expertise to be based on a multidisciplinary approach to care when addressing rare diseases. **EUROPLAN recommendations** R 4.2 Healthcare pathways are defined and adopted, based on best practices and expertise at national and international level. R 4.6 Centres of expertise provide proper training to paramedical specialists; paramedical good practices are coordinated, in order to serve the specific rehabilitation needs of rare diseases patients. R 4.12 The adoption of an ad hoc coding is promoted, when appropriate, to recognise and appropriately resource and reimburse the special rehabilitation treatments necessary for rare diseases. **EUCERD Recommendations on Quality Criteria for CEs**	• Do CEs in your country based on a multidisciplinary approach? Are they capable of bringing together, or coordinating, 'within the specialised healthcare sector, multidisciplinary competences/skills, including paramedical skills and social services, in order to serve the specific medical, rehabilitation and palliative needs of rare diseases patients'? (*EUCERD Recommendations*) • Do CEs have links with specialised laboratories and other facilities? • What opportunities are provided for "**education and training** to healthcare professionals from all disciplines, including paramedical specialists and non-healthcare professionals (such as school teachers, personal/homecare facilitators) whenever possible"? "Clinical or **healthcare pathways** are structured, multidisciplinary plans of care designed to support the implementation of clinical guidelines or protocols." (EUROPLAN Recommendations, page 46, par. 64). • How do CEs contribute to build "healthcare pathways" from primary care? How to develop a system based on the adoption of healthcare pathways for the provision of care? • How do CEs link to local structures providing day-to day care? • In particular, how to link medical expertise of the specialised CEs to local medical,

"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)" 4. CEs bring together, or coordinate, within the specialised healthcare sector multidisciplinary competences/skills, including paramedical skills and social services, in order to serve the specific medical, rehabilitation and palliative needs of rare diseases patients. 5. CEs contribute to building healthcare pathways from primary care. 9. CEs provide education and training to healthcare professionals from all disciplines, including paramedical specialists and non-healthcare professionals (such as school teachers, personal/homecare facilitators) whenever possible. **"Criteria for designation of CEs for RD in MS"** 25. Demonstration of a multi-disciplinary approach, when appropriate, integrating medical, paramedical, psychological and social needs (e.g. RD board). 26. Organisation of collaborations to assure the continuity of care between childhood, adolescence and adulthood, if relevant. 27. Organisation of collaborations to assure the continuity of care between all stages of the disease. **Final Report of EUROPLAN I National Conferences** (Area 4, page 43) - "Structures have to be developed to coordinate day-to-day care within an acceptable travel distance, while expert care should be organised in Centres of Expertise (diagnosis, establishing a care plan, regular check-up, certain emergencies, etc.). These structures may be information platforms or tools able to functionally connect the centres with the other structures involved in the continuity of patients' care."	paramedical and social care? • What solutions are provided for to support the mobility of expertise from CEs to local care providers, so as to allow the **treatment of patients in their proximity**? Specifically, what e-heath solutions could support the task? *(see above B.2., High level of expertise and mobility of expertise)* • What mechanisms can be found to recognise the paramedical and rehabilitation interventions (provided that they are prescribed by the CE), to integrate them into the reimbursement schemes and to simplify the procedures for reimbursement? (see EUROPLAN Recommendation R 4.12 and Final Report of EUROPLAN I Conferences) • Do CEs take into account the **ageing** of patients? Do they envisage "collaborations to assure the continuity of care between childhood, adolescence and adulthood, if relevant?" (EUCERD Recommendations) • Is it envisaged that CEs organise "collaborations to assure the continuity of care between **all stages of the disease**"? How are these collaborations ensured in practical terms?
B.4 Access to information	
EUCERD Recommendations on Quality Criteria for CEs **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 10. CEs contribute to and provide accessible information adapted to the specific needs of patients and their families, of health and social professionals, in collaboration with patient organisations and with Orphanet.	• How do CEs "provide accessible information adapted to the specific needs of patients and their families, of health and social professionals, in collaboration with patient organisations and with Orphanet"? (EUCERD Recommendations) • In particular, what role do patient associations have in the provision of accessible information tailored to the needs of different users?

B.5 Research in CEs – How to integrate research on RDs and provision of care	
EUCERD Recommendations on Quality Criteria for CEs **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 13. CEs contribute to research, to improve the understanding of the disease and to optimise diagnosis, care and treatment, including the clinical evaluation of long-term effects of new treatments. **"Criteria for designation of CEs for RD in MS"** 22. Contribution to state-of-the-art research. 23. Capacity to participate in data collection for clinical research and public health purposes. 24. Capacity to participate in clinical trials, if applicable.	• What is the role of CEs in research? Do they contribute 'to improve the understanding of the disease and to optimise diagnosis, care and treatment, including the clinical evaluation of long-term effects of new treatments'?(*EUCERD Recommendations*) • Do they contribute to state of the art research on relevant RDs? Do they have the capacity to participate in clinical trials?
B.6 Good practice guidelines	
EUCERD Recommendations on Quality Criteria for CEs **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 8. CEs contribute to the elaboration of good practice guidelines and to their dissemination. **"Criteria for designation of CEs for RD in MS"** 17. Capacity to produce and adhere to good practice guidelines for diagnosis and care. **Final Report of EUROPLAN I Conferences** (Area 5, page 51) - "Good practice guidelines should align actions performed at different levels of care and by different healthcare professionals, with specific information for patients, families, caregivers and teachers**".** (Area 4, page 47) - "Providing contributions to European recommendations or guidelines should be also an activity performed by CoEs."	• How do CEs "contribute to the elaboration of good practice guidelines and to their dissemination"? (EUCERD Recommendations)? • How are patient and their representatives involved in their development? • How do CEs coordinate among themselves or network with other similar bodies to develop good practice guidelines? • How could experts and CEs better contribute to the development of international/European good practice guidelines? • What measures do exist to adopt and/or adapt guidelines developed in other countries or by other international bodies where they do not exist for those specific diseases, so as optimise efforts and resources? • Do CEs recognise and adhere to existing good practice guidelines for the RDs they deal with?

B.7 Diagnostic and genetic testing	
Council Recommendation on RD 17. Gather national expertise on rare diseases and support the pooling of that expertise with European counterparts in order to support: (a) the sharing of best practices on diagnostic tools and medical care as well as education and social care in the field of rare diseases; (c) the development of medical training in fields relevant to the diagnosis and management of rare diseases, such as genetics, immunology, neurology, oncology or paediatrics; (d) the development of European guidelines on diagnostic tests or population screening, while respecting national decisions and competences; **EUCERD Recommendations for Quality Criteria for CEs** **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 1. CEs tackle diseases or conditions requiring specific care due to the difficulty in establishing a diagnosis, to prevent complications and/or to set up treatments. 6. CEs have links with specialised laboratories and other facilities. **"Criteria for designation of CEs for RD in MS"** 17. Capacity to produce and adhere to good practice guidelines for diagnosis and care. 31. Appropriate arrangements to improve the delivery of care and especially to shorten the time taken to reach a diagnosis. **EUROPLAN Recommendations** R 4.5 Travelling of biological samples, radiologic images, other diagnostic materials, and e-tools for tele-expertise are promoted. R 4.7 A national framework is ensured on rare diseases screening options and policies. R 4.8 Proper performance of newborn screenings prescribed in the country is monitored with appropriate indicators. R 4.9 Accessibility to genetic counselling is promoted. R 4.10 The quality of genetic testing and other diagnostic tests is ensured, including participation in external quality control schemes at national and international level. R 4.11 A national inventory of medical laboratories providing testing for rare disease is compiled and made publicly available.	**Good practice guidelines** See above B.6. on good practice guidelines for both diagnosis and healthcare. **Diagnostic laboratories** • How to compile an inventory of medical laboratories providing testing for RD? • Is there an accreditation process for such laboratories based on quality criteria? • How to ensure support and networking of such laboratories in order to have dedicated infrastructures and resources for the biological component of RDs? How to better link them to CEs in a structured way? How to ensure partnership with laboratories outside the country when not available at national level? **Travelling of diagnostic material and tele-expertise** • What arrangements do exist to enable the travelling of biological samples, radiological images as well as other diagnostic material? • How to organise DNA and sample exchanges at the European and national level? What sort reimbursement agreements and policies do support these exchanges? See also above B.2. "High level of expertise and mobility of expertise" **Genetic counselling** • What measures are in place to ensure direct families are directed towards the most appropriate diagnostic testing and rare disease centres of expertise? • Is competent genetic counselling an integral part of genetic testing and made easily accessible and provided before and after genetic testing in CEs? Is it provided by adequately trained healthcare professionals? • How to best integrate the EuroGenTest recommendations on genetic counselling (http://www.eurogentest.org/web/files/public/unit3/guidelines%20of%20GC%20final.pdf) into national practices?

Final Report of EUROPLAN I Conferences (Area 4, page 47) - "Competent genetic counselling should be made easily accessible and provided before and after genetic testing, in regional centres or CoEs (Romania). - In some countries the medical speciality of "Clinical genetics" does not exist. It is recommended that it be introduced as soon as possible in the university system. - Strict quality control and evaluation of genetic testing should be fulfilled. External quality controls programmes should be also implemented. - It was frequently demanded that an inventory of medical laboratories providing testing for RDs be compiled. This was sometimes supported by the request for accreditation of such laboratories (e.g. Romania, France). - In France, in particular, the Second NP, in addition to CoE and their networks, introduces the 'reference laboratories' and the networks of such laboratories, in order to have dedicated infrastructures (and resources) for the biological component, often neglected in CoEs, where treatment and care are usually provided as a priority." **EuroGenTest Recommendations on Genetic Counselling** http://www.eurogentest.org/web/files/public/unit3/guidelines%20of%20GC%20final.pdf	
B.8 Screening policies	
Council Recommendation on RD 17. Gather national expertise on rare diseases and support the pooling of that expertise with European counterparts in order to support: (d) the development of European guidelines on diagnostic tests or population screening, while respecting national decisions and competences **EUROPLAN Recommendations** R 4.7 A national framework is ensured on rare diseases screening options and policies. R 4.8 Proper performance of newborn screenings prescribed in the country is monitored with appropriate indicators. **Executive Report to the European Commission on newborn screening in the European Union** http://ec.europa.eu/eahc/documents/news/Executive_Report_to_EC_20120108_FINALE.pdf In particular, see below in section B.5 the following chapters in full:	**National legal framework** • What population screening programmes exist in your country? In particular, which newborn screening programmes? • What measures are in place or should be adopted to ensure that existing newborn screening programmes are as comprehensive as possible? • What measures could be put in place to evaluate and then to improve their performance and their actual coverage of population? • What policies are envisaged to monitor changes in the population which can justify the provision of targeted screening practices? • What legal basis supports the newborn screening practices? If newborn screening practices are made mandatory, are they accompanied by the necessary transparent and clear information to parents? "The national legal basis might furthermore regulate consistently the following issues: - the storage and the delayed use of samples and the associated consent; - the identification of eligible benefits; - the communication of results to parents and/or patients, including

”B. Areas that could benefit from the development of an EU policy on NBS”, page 7; “C. Actions proposed to facilitate the development of EU policies in the field of neonatal screening”, page 10. **Final Report of EUROPLAN I Conferences** (Area 5, page 46) - “A good legal basis is essential to frame RD screening policies. Also, running common surveys to assess the feedback of RD stakeholders on these topics may be of great value. - Implementation is also essential. The case of Romania, where a dedicate session of the workshop focused on screening, shows how in actual fact the lack of resources or of appropriate screening centres, or the lack of consistent application of the existing policy create important gaps in detection of RDs and delays/mistakes in diagnosis. Screening policies should be therefore accompanied by evaluation procedures to assess the quality and performance of the programmes.” (Area 5, page 47) - “Extension of the current neonatal screening programmes is demanded by many Conferences, as they are considered relatively limited. At present, more diseases can be reliably diagnosed (not too many false positives or negatives), for which early treatment would be beneficial. - An international exchange on the effectiveness and regulations of newborn screening should be promoted further. The outcomes of the EC-funded project on neonatal screening of RD in Europe, which aims at issuing recommendations for good practices, is awaited.”	unintended findings; - the collection and communication of data for the assessment of the programme and for improving the knowledge on disease and treatment; - ensure quality control and quality assurance - sustain funding. “ (*see Executive Report to the EC on Newborn Screening in the EU*) **Decision making process** • How to ensure that the **decision-making process** is associated to the national technology assessment process? • What arrangements could be envisaged to involve patients and patient groups in the decision-making process for including additional newborn screening practices? **Collaboration at the EU level** • How to enable **collaboration at EU level**, notably to deal with the assessment of elements that are common to all countries and better dealt with at the EU level (e.g. efficacy of treatments, reliability of screening tests) without impairing the national competence? • Does your country participate to existing committees ensuring collaborative efforts in this field e.g. the EUnetHTA (www.eunethta.eu)? • How to facilitate sharing documents and experiences for the benefit of countries which have not the material available yet? **Awareness and training** • What **training courses** could be provided for all stage of newborn screening, and in particular regarding the communication to parents of the diagnostic suspicion and of positive confirmed diagnoses? • What specific support and funding could be provided to patient groups with regard to patient empowerment after diagnosis? E.g. providing guidelines or directive regulating the involvement of professions in the treatment of patients with disorders they screen for. • In addition to newborn screening policies, which concern only a limited number of RDs, what measures could be put in place to enable doctors and in particular neonatologists to investigate unusual symptoms in newborns? • What specific training programmes could be developed by CEs for this purpose?

B.9 European and international collaboration – Cross-border healthcare and ERNs (European Reference Networks)	
Council Recommendation Whereas: […] (13) …ERNs could also serve as research and knowledge centres, treating patients from other Member States and ensuring the availability of subsequent treatment facilities where necessary. (14) The Community added value of ERNs is particularly high for rare diseases by reason of the rarity of these conditions, which implies both a limited number of patients and a scarcity of expertise within a single country. Gathering expertise at European level is therefore paramount in order to ensure equal access to accurate information, appropriate and timely diagnosis and high quality care for rare disease patients. (The Council of the EU) hereby recommends that Member States: … 12. Foster the participation of centres of expertise in European reference networks respecting the national competences and rules with regard to their authorisation or recognition. **EUCERD Recommendations on Quality Criteria for CEs** **"Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)"** 12. According to national/international ethical and legal frameworks, CEs should ensure respect of non-discrimination and non-stigmatisation of RD patients across Europe, within their sphere of competencies. 15. CEs liaise with other CEs at National and European level when relevant. **"Criteria for designation of CEs for RD in MS"** 28. Links and collaboration with other CE at national, European and international level. 30. Appropriate arrangements for referrals within individual Member States and from/to other EU countries if applicable. **EUROPLAN Recommendations** R 4.3 Cross-border healthcare should be promoted, where appropriate. In that case,	**Patients' rights to cross-border healthcare** • What national measures need to be adapted or changed in order to comply with the CBHC and ensure equality of access and treatment of patients from all over the EU? • How is the country defining the **list of treatments for which prior authorisation** is required according to the CBHC Directive? How to avoid too narrow definitions that could hamper the referrals of rare disease patients to healthcare providers abroad? • When a **CE sends a patient abroad for a second opinion**, is the authorisation automatically delivered? Although not compulsory under the CBHC rules, this is essential, as the decision of a recognised expert cannot be put into question. • Is the country setting up **National Contact Points** as per the CBHC Directive? Are they equipped with information on which type of care is available in other EU countries, costs, rights and practical aspects on cross border care that will be received, in order to enable patients to make an informed choice? • What other measures are envisaged to address the specific information needs of healthcare professionals, patient organisations and citizens in general? • Is reimbursement of **travel and accommodation costs** covered for patients travelling abroad under the EU rules? Member States have the option to cover or not these "other costs" (article 7.4 of the CBHC Directive), but these costs are unavoidable for RD patients as expertise can often only be found abroad. • What **e-Health** measures are being put in place to enhance cooperation with other EU countries to have access to the patient's written or electronic medical records of patients who are travelling for healthcare aboard? What solutions are being put in place to ensure that this data is fully readable and understandable and that different health IT systems "talk to each other"? **European Reference Networks (ERNs)** • What national legislative measures do need to be put in place in order to support the **development of ERN** between healthcare providers and CEs? In particular: - What specific measures do foster the connection of CEs and healthcare providers throughout the country and their sharing of information (as a precondition of their participation to ERNs)? - What specific measures to encourage CEs and healthcare providers to participate and contribute to ERNs? • What level of awareness and participation does exist in the country as to the

centres able to provide quality diagnosis and care are identified in neighbouring or other countries, where patients or biological samples can be referred to, and cooperation and networking is promoted. **EUCERD Recommendations for Quality Criteria for CEs** **The European dimension of CEs** 41. MS with established CEs share their experience and quality indicators with other MS and coordinate their efforts to identify CEs for all RD patients at EU level. 42. Networking of CEs is a key element of their contribution to patient diagnosis and care, to ensure that expertise travels rather than patients themselves when appropriate; exchange of data, biological samples, radiological images, other diagnostic materials, and e-tools for tele-expertise are promoted. 43. Cross-border healthcare is organised, where appropriate, with designated CEs in neighbouring or other countries, where patients or biological samples can be referred to. 44. Member States should provide adequate information to professionals, citizens and patients organisations concerning the possibilities and conditions of access to health care at national and international levels in the field of rare diseases. 45. Designated CEs at MS level are the key elements of the future ERNs. **EU Directive on Cross Border Health Care (CBHC Directive)** http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF **EURORDIS Q&A on Cross-border Healthcare Directive** http://e-news.s3.amazonaws.com/Q%26A_cross_border_care_final-1.pdf **European Commission - Q&A on Patients' Rights in Cross Border Healthcare** http://europa.eu/rapid/press-release_MEMO-11-32_en.htm?locale=en	**criteria** that will be established at EU level: 1) specific criteria and conditions that ERN and the healthcare providers wishing to join the network must fulfil; 2) criteria to establish and assess ERNS. Are the national authorities ready to participate to the definition of these criteria? How to transpose them at national level when the criteria are adopted? ***NB – in 2013 the EUCERD will adopt Recommendations on ERNs so this paragraph will be reviewed further.***
B.10 Sustainability of CEs	
EUROPLAN Recommendations (par. 61 page 44) **"**61. From the experience of the few member states where centres of expertise exist, it is clear that specific funding is deemed necessary to ensure long-term sustainability of such centres. Long-term sustainability is needed for the benefit of the	• What mechanisms are at national level ensure that CEs are established and operate in line with a sustainable plan? • How is the long-term sustainability of CEs accounted for? What mechanisms do exist to verify the long-term sustainability of CEs at the moment of designation?

patients, and ensures collation and maintenance of the knowledge and experience developed in the centre as well as the continuity of care. In addition centres of expertise are often called to bear special costs and administrative efforts due to the complexity of rare diseases and the high costs of treatments." R 4.1 Well defined mechanisms of designation of centres of expertise are established and their quality is assured, efficiency and long term sustainability. **Final Report of EUROPLAN I Conferences** (Area 4, page 44) - "Solutions should be found for the performance of activities which go beyond the treatment (purely healthcare services), recognised as fundamental for CoEs, yet often underperformed due to the lack of fund, reimbursement provisions, human resources or time. - In France, the Second NP allocates funds for "Missions d'intérêt générale" to CoEs and introduces a system of funding based not on the single centre, but on funds dedicated to certain activities recognised as "missions of general interest". This allows creating resources for activities not strictly related to patient treatment, such as clinical research, production of guidelines for diagnosis and care; in-depth clinical and biological investigations; coordination of international networks, etc. - Finally, it has been raised (Spain) that in countries qualifying for it, RDs should be included in included in the "Cohesion budget" also available for health objectives, usually managed by the Ministry for Health."	And at the moment of evaluation? • How are activities performed by the CEs but not strictly related to patient treatment (e.g. as clinical research, production of guidelines for diagnosis and care; in-depth clinical and biological investigations; coordination of international networks, etc.) funded? • How to make best use of **Structural Funds** in the forthcoming period 2014-2020? • Is there scope for investments in rare disease CEs in the national strategic reference frameworks (NSRFs) for Structural Funds (ERDF, ESF*, Cohesion Fund)? • Are there in the country specific Operational Programmes for Health where projects for RDs infrastructures and human resources could be included? * ERDF European Regional Development Fund ; ESF European Structural Fund

C. Background documents

C.1 Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02)

Whereas:
[…]
(13) In July 2004, a Commission High-Level Group on Health Services and Medical Care was established to bring together experts from all Member States to work on practical aspects of collaboration between national health systems in the EU. One of this High-Level Group's working groups is focusing on European Reference Networks (ERNs) for rare diseases. Some criteria and principles for ERNs have been developed, including their role in tackling rare diseases. ERNs could also serve as research and knowledge centres, treating patients from other Member States and ensuring the availability of subsequent treatment facilities where necessary.

(14) The Community added value of ERNs is particularly high for rare diseases by reason of the rarity of these conditions, which implies both a limited number of patients and a scarcity of expertise within a single country. Gathering expertise at European level is therefore paramount in order to ensure equal access to accurate information, appropriate and timely diagnosis and high quality care for rare disease patients.

(15) In December 2006 an expert group of the European Union Rare Diseases Task Force issued a report 'Contribution to policy shaping: for a European collaboration on health services and medical care in the field of rare diseases' to the High-Level Group on Health Services and Medical Care. The expert group report outlines, inter alia, the importance of identifying centres of expertise and the roles that such centres should fulfil. It is also agreed that, in principle and where possible, expertise should travel rather than patients themselves. Some measures called for in the report are included in this recommendation.

(16) Cooperation and knowledge sharing between centres of expertise has proven to be a very efficient approach to dealing with rare diseases in Europe.

(17) The centres of expertise could follow a multidisciplinary approach to care, in order to address the complex and diverse conditions implied by rare diseases.

(The Council of the EU) hereby recommends that Member States:
[…]
"IV. CENTRES OF EXPERTISE AND EUROPEAN REFERENCE NETWORKS FOR RARE DISEASES
11. Identify appropriate centres of expertise throughout their national territory by the end of 2013, and consider supporting their creation.

12. Foster the participation of centres of expertise in European reference networks respecting the national competences and rules with regard to their authorisation or recognition.

13. Organise healthcare pathways for patients suffering from rare diseases through the establishment of cooperation with relevant experts and exchange of professionals and expertise within the country or from abroad when necessary.

14. Support the use of information and communication technologies such as telemedicine where it is necessary to ensure distant access to the specific healthcare needed.

15. Include, in their plans or strategies, the necessary conditions for the diffusion and mobility of expertise and knowledge in order to facilitate the treatment of patients in their proximity.

16. Encourage centres of expertise to be based on a multidisciplinary approach to care when addressing rare diseases."

V. GATHERING THE EXPERTISE ON RARE DISEASES AT EUROPEAN LEVEL
17. Gather national expertise on rare diseases and support the pooling of that expertise with European counterparts in order to support:

(a) the sharing of best practices on diagnostic tools and medical care as well as education and social care in the field of rare diseases;

(b) adequate education and training for all health professionals to make them aware of the existence of these diseases and of resources available for their care;

(c) the development of medical training in fields relevant to the diagnosis and management of rare diseases, such as genetics, immunology, neurology, oncology or paediatrics;

(d) the development of European guidelines on diagnostic tests or population screening, while respecting national decisions and competences;

(e) the sharing Member States' assessment reports on the therapeutic or clinical added value of orphan drugs at Community level where the relevant knowledge and expertise is gathered, in order to minimise delays in access to orphan drugs for rare disease patients.

http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF

C.2 EUCERD Recommendations on quality Criteria for Centre of Expertise for Rare Diseases in Member States

http://www.eucerd.eu/?post_type=document&p=1224

Executive summary (http://www.eucerd.eu/?page_id=13)**:**

On the 24 October 2011, during the third meeting of the EUCERD, the EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States were unanimously adopted by the 51-member EUCERD.

There are around 6000 rare diseases and most are unknown to healthcare professionals so rare diseases patients suffer from not knowing where to consult. To overcome this, some Member States have established centres specialised in some rare diseases/groups of rare diseases which have proven to be very efficient in improving quality of care. In order to help other countries elaborate similar processes, the EUCERD has established this set of Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States.

The development of centres of expertise and European Reference Networks in the field of rare diseases is encouraged in the Council Recommendation on an Action in the Field of Rare Diseases (2009/C 151/02) (8 June 2009) and more recently in the Directive on the application of patients' rights in cross-border healthcare (2011/24/EU) (9 March 2011) as a means of organising care for the thousands of heterogeneous rare conditions affecting scattered patient populations across Europe. In order to share knowledge and expertise more efficiently, the EUCERD recommendations seek to introduce harmonious standards of quality practices by elaborating criteria for the Member States to incorporate into their process to designate centres of expertise, especially in the context of national plans/strategies for rare diseases which the Council has urged all Member States to elaborate by 2013.

EUCERD, formally the EC Rare Diseases Task Force, has already issued a series of reports investigating the state-of-the-art in the field. The 45 Recommendations build upon these previous achievements and will serve to assist the Member States in developing their healthcare pathways at both the national and EU levels in the field of rare diseases. The recommendations cover the mission and scope of the centres of expertise at Member State level; the criteria for designating centres of expertise in Member States; the process of designating and evaluating centres of expertise in Member States; and the European dimension of centres of expertise.

Mission and scope of centres of expertise (CEs) for rare diseases (RD) in Member States (MS)

1. CEs tackle diseases or conditions requiring specific care due to the difficulty in establishing a diagnosis, to prevent complications and/or to set up treatments.
2. CEs are expert structures for the management and care of RD patients in a defined catchment area, preferably national, and at international level if necessary.
3. The combined scope of all CEs within a MS covers all RD patients' needs, even if they cannot provide a full range of services with the same level of expertise for each RD.
4. CEs bring together, or coordinate, within the specialised healthcare sector multidisciplinary competences/skills, including paramedical skills and social services, in order to serve the specific medical, rehabilitation and palliative needs of rare diseases patients.
5. CEs contribute to building healthcare pathways from primary care.
6. CEs have links with specialised laboratories and other facilities.
7. CEs collaborate with patient organisations to bring in the patients' perspective.
8. CEs contribute to the elaboration of good practice guidelines and to their dissemination.
9. CEs provide education and training to healthcare professionals from all disciplines, including paramedical specialists and non-healthcare professionals (such as school teachers, personal/homecare facilitators) whenever possible.
10. CEs contribute to and provide accessible information adapted to the specific needs of patients and their families, of health and social professionals, in collaboration with patient organisations and with Orphanet.
11. CEs respond to the needs of patients from different cultures and ethnic groups (i.e. have cultural sensitivity).

12. According to national/international ethical and legal frameworks, CEs should ensure respect of non-discrimination and non-stigmatisation of RD patients across Europe, within their sphere of competencies.

13. CEs contribute to research, to improve the understanding of the disease and to optimise diagnosis, care and treatment, including the clinical evaluation of long-term effects of new treatments.

14. The scope of diseases covered by each CE, or by a CE at national level, will vary depending on the size of the country and the structure of the national health care system.

15. CEs liaise with other CEs at National and European level when relevant.

16. A national directory of formally designated CEs is compiled and made publicly available, including on the Orphanet portal.

Criteria for designation of CEs for RD in MS

17. Capacity to produce and adhere to good practice guidelines for diagnosis and care.

18. Quality management in place to assure quality of care, including National and European legal provisions, and participation in internal and external quality schemes when applicable.

19. Capacity to propose quality of care indicators in their area and implement outcome measures including patient satisfaction.

20. High level of expertise and experience documented, for instance, by the annual volume of referrals and second opinions, and through peer-reviewed publications, grants, positions, teaching and training activities.

21. Appropriate capacity to manage RD patients and provide expert advice.

22. Contribution to state-of-the-art research.

23. Capacity to participate in data collection for clinical research and public health purposes.

24. Capacity to participate in clinical trials, if applicable.

25. Demonstration of a multi-disciplinary approach, when appropriate, integrating medical, paramedical, psychological and social needs (e.g. RD board).

26. Organisation of collaborations to assure the continuity of care between childhood, adolescence and adulthood, if relevant.

27. Organisation of collaborations to assure the continuity of care between all stages of the disease.

28. Links and collaboration with other CE at national, European and international level.

29. Links and collaboration with patient organisations where they exist.

30. Appropriate arrangements for referrals within individual Member States and from/to other EU countries if applicable.

31. Appropriate arrangements to improve the delivery of care and especially to shorten the time taken to reach a diagnosis.

32. Consideration of E-Health solutions (e.g. shared case management systems, expert systems for tele-expertise and shared repository of cases).

Process for designating and evaluating CEs for RD in MS

33. MS take action concerning the establishment and designation and evaluation of CEs and facilitate access to these centres.

34. MS establish a procedure to define and approve designation criteria and a transparent designation and evaluation process.

35. The designation criteria defined by MS are adapted to the characteristics of the disease or group of diseases covered by the CE.

36. CEs may not fulfill some of the designation criteria defined by the MS as long as the absence of fulfillment of those criteria does not impact on the quality of care and as long as CEs have a strategy in place to attain designation criteria in a defined time period.

37. The designation process at MS level ensures that the designated CEs have the capacity, and the resources to fulfill the obligations of designation.

38. The designation of a CE is valid for a defined period of time.

39. CE are re-evaluated on a regular basis through a process incorporated into the designation process at MS level.

40. The designating authority at MS level may decide to withdraw the designation of a centre of expertise if one or more of the conditions that formed the basis for designation is no longer satisfied, or if there is no longer a need to maintain the national service.

The European dimension of CEs

41. MS with established CEs share their experience and quality indicators with other MS and coordinate their efforts to identify CEs for all RD patients at EU level.

42. Networking of CEs is a key element of their contribution to patient diagnosis and care, to ensure that expertise travels rather than patients themselves when appropriate; exchange of data, biological samples, radiological images, other diagnostic materials, and e-tools for tele-expertise are promoted.

43. Cross-border healthcare is organised, where appropriate, with designated CEs in neighbouring or other countries, where patients or biological samples can be referred to.

44. Member States should provide adequate information to professionals, citizens and patients organisations concerning the possibilities and conditions of access to health care at national and international levels in the field of rare diseases.

45. Designated CEs at MS level are the key elements of the future ERNs.

C.3 EUROPLAN Recommendations

EUROPLAN recommendations on Area 4: Centres of Expertise and European Reference Networks for rare diseases

R 4.1 Well defined mechanisms of designation of centres of expertise are established and their quality is assured, efficiency and long term sustainability.

R 4.2 Healthcare pathways are defined and adopted, based on best practices and expertise at national and international level.

R 4.3 Cross-border healthcare should be promoted, where appropriate. In that case, centres able to provide quality diagnosis and care are identified in neighbouring or other countries, where patients or biological samples can be referred to, and cooperation and networking is promoted.

R 4.4 A national directory of Centres of expertise is compiled and made publicly available.

R 4.5 Travelling of biological samples, radiologic images, other diagnostic materials, and e-tools for tele-expertise are promoted.

R 4.6 Centres of expertise provide proper training to paramedical specialists; paramedical good practices are coordinated, in order to serve the specific rehabilitation needs of rare diseases patients.

R 4.7 A national framework is ensured on rare diseases screening options and policies.

R 4.8 Proper performance of newborn screenings prescribed in the country is monitored with appropriate indicators.

R 4.9 Accessibility to genetic counselling is promoted.

R 4.10 The quality of genetic testing and other diagnostic tests is ensured, including participation in external quality control schemes at national and international level.

R 4.11 A national inventory of medical laboratories providing testing for rare disease is compiled and made publicly available.

R 4.12 The adoption of an ad hoc coding is promoted, when appropriate, to recognize and appropriately resource and reimburse the special rehabilitation treatments necessary for rare diseases.

EUROPLAN recommendations on Area 5: Gathering the expertise on rare diseases at European level

R 5.1 The use of international global information websites and data repositories for rare diseases is promoted.

R 5.2 Access to knowledge repositories and to expert advice for health professionals is established.

R 5.3 Information on how to establish or join a European reference Network is made available for to health professionals.

R 5.4 The curriculum of the medical degree course includes an education package on rare diseases and on the relevant, specific provisions in the healthcare services.

R 5.5 Training of medical doctors (general practitioners and specialists), scientists and new healthcare professionals in the field of rare diseases is supported.

R 5.6 Continuing education programmes on rare diseases are made available for health professionals.

R 5.7 The exchange and sharing of expertise and knowledge between centres within the country and abroad is promoted.

R 5.8 Collaboration is ensured in the European evaluation of the existing screening programs.

R 5.9 The development and adoption of good practice guidelines for rare diseases is promoted. The guidelines are made publicly available and disseminated as of the reach targeted health professionals.

R 5.10 Dissemination of the information about treatment for rare diseases is ensured in the most effective way, to avoid delays of treatment accessibility.

R 5.11 Participation is ensured in common mechanisms, when available, defining conditions for the off-label use of approved medicinal products for application to rare diseases; for facilitating the use of drugs still under clinical trial; for compassionate provision of orphan drugs.

R 5.12 An inventory of orphan drugs accessible at national level, including reimbursement status, is compiled and made publicly available.

R 5.13 Patients' access to authorised treatment for rare disease including reimbursement status, is recorded at national and/or EU level.

R 5.14 The list of on-going clinical trials on Orphan Medicinal Products included in the European database for clinical trials on Orphan Medicinal Products (EUDRA) is made public at national level.

R 5.15 All information on centres of expertise, good practice guidelines, medical laboratory activities, clinical trials, registries and availability of drugs, collected at national level, is also published on Orphanet as planned in the Joint Action.

http://www.europlanproject.eu/_newsite_986987/_down/results/2008-2011_2.EUROPLANGuidance.pdf

C.4 EUROPLAN Indicators

Area to be explored	Aims	Actions	Indicators		Type of indicator	Answers
Centres of Expertise and European Reference Networks for Rare Diseases	Identify and/or establish national/regional centres of expertise and European reference network of centres	Improve the quality of health care by defining appropriate centres with experience on RD as well as pathways* (*see operative definition below*) that reduce the diagnosis delay and facilitate the best both cares and treatments to patients	**4.1.**	**Existence of a policy for establishing centres of expertise at the national/regional level**	Process	• *Not existing, not clearly stated* • *Existing, clearly stated, partly implemented* • *Existing, clearly stated and substantially implemented*
			4.2.	**Number of centres of expertise adhering to the policy defined in the country**	Outcomes	*Number of reference centres*
			4.3.	**Groups of rare diseases followed up in centres of expertise**	Outcomes	*Computation must be referred to the whole country:* • *Covering all or most of rare diseases* • *Covering only some rare diseases*
			4.4.	**Centres of expertise adhering to the standards defined by the Council Recommendations -paragraph d) of preamble**	Outcomes	*Percentage of centres of expertise adhered by the total of centres of expertise designed*
			4.5.	**Participation of national or regional centres of expertise into European reference networks**	Outcomes	*Index based on Number of centres of expertise cooperating with ERN by number of total of centres of expertise designed*

***Care Pathway -** The European Pathway Association defines a clinical/care pathway as: Care pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of care pathways includes:

- An explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations;
- The facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives;

- The documentation, monitoring, and evaluation of variances and outcomes; and
- The identification of the appropriate resources.
- The aim of a care pathway is to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources.

Area to be explored	Aims	Actions	Indicators		Type of indicator	Answers
Gathering the expertise on Rare Diseases at European level	Improving education and training	Existence of a information sites for professionals provided by the plan/strategy	**5.1.**	**Existence of a comprehensive national and/or regional RD information system supported by the government**	Process	• *Yes, covers most RD* • *Yes, covers only some RD* • *Not formal decisions have been taken*
			5.2.	**Help lines for professionals**	Process	• *Yes, covers most RD* • *Yes, covers only some RD* • *Not formal decisions have been taken*
			5.3.	**Clinical guidelines**	Outcomes	*Number ranging between 0 to 30*
		Promoting training activities and awareness educational campaigns among professionals	**5.4.**	**Number of such as activities promoted by the plan/strategy**	Process	*Number ranging between 0 to 30*
	Ensuring early and accurate diagnosis	Develop screening policies	**5.5.**	**Number of diseases included in the neonatal screening programme**	Outcomes	*Number of diseases*
			5.6.	**Number of diseases included in the neonatal screening programme properly assessed**	Outcomes	*Index based on the number of disease tests assessed and included in the neonatal screening programme divided by the total number of diseases included in the neonatal screening program.*
		Ensure quality of RD diagnosis laboratory	**5.7.**	**Existence of a public directory/ies of both genetic tests on Rare Diseases**	Process	• Yes • No • Under discussion
			5.8.	**Proportion of laboratories having at least one diagnostic test validated by an external quality control**	Outcomes	*Number of validated RD laboratories divided by the total number of RD laboratories*
	To ensure and accelerate accessibility to	Ensure the mechanism that facilitates ODD access and the	**5.9**	**Number of ODD market authorizations by EMEA and placed in the market in the country**	Outcomes	*Index based on Number of ODD placed in the market by total of ODD approved by the EMEA*

	Orphan Designated Drugs (ODD) ***!! (This sub-area is deal with in Workshop 5 of EUROPLAN II National Conferences)***	reimbursement of their cost to patients after they got the market authorization by EMEA.	**5.10**	**Time between the date of a ODD market authorization by EMEA and its actual date of placement in the market for the country**	Outcomes	*Average days since the date of market authorization by EMEA until the official date of placement in the market in the country*
			5.11	**Time from the placement in the market in the country to the positive decision for reimbursement by public funds**	Outcomes	*Average days since the date of placement in the market until the reimbursement decision date in the country*
			5.12	**Number of ODD reimbursed 100%**	Outcomes	*Number ranging 0 to 1,000*
		To develop mechanisms to accelerate ODD availability	**5.13**	**Existence of a governmental program for compassionate use for Rare Diseases**	Outcomes	• *No* • *Yes* • *In process*

C.5 Executive Report to the European Commission on newborn screening in the European Union

EU Tender - "Evaluation of population newborn screening practices for rare disorders in Member States of the European Union"

Authors: Luciano Vittozzi1, Peter Burgard[2], Martina Cornel[3], Georg F. Hoffmann[2], Martin Lindner[2], J. Gerard Loeber4, Tessel Rigter[3], Kathrin Rupp[2], Domenica Taruscio1, Stephanie Weinreich[3].

1: National Centre for Rare Diseases, National Institute for Health - Rome (IT)
2: Department of Paediatrics, University of Heidelberg (DE)
3: VU University Medical Center - Amsterdam (NL)
4: RIVM - Bilthoven (NL)

B. Areas that could benefit from the development of an EU policy on NBS

Neonatal screening encompasses the whole system from information to prospective parents to treatment of those infants who have been identified as having one of the screened conditions. Neonatal screening in most countries is offered under the responsibility of the public health system. Yet in many countries the health system does not care for the collection and exchange of information between the confirmatory diagnostic, treatment and follow-up phases, which may prove invaluable for the quality of NBS.

There are a number of areas and steps of the whole neonatal screening system which show room for a feasible improvement by means of a dedicated EU policy, especially if it can benefit from synergies deriving from a coordinated action of the EU.

1. Decision-making framework

A structured framework, representing in a balanced way the views and needs of the patients and other citizens, the national health systems and other institutional stakeholders, such as social insurances and governmental scientific experts, could be defined at EU level consisting of three steps:

a. EU-level technology assessment

The Community level technology assessment deals with the general and intrinsic features of a disease candidate for screening; it could receive and assess dossiers, submitted by interested parties, supporting disease candidates for neonatal screening. It might also assess spontaneously new technological developments (horizon scanning). This activity could be carried out in association or collaboration with existing European countries collaborative mechanisms, such as EUNetTHA4.

4 http://

b. National (regional) technology assessment

The national (regional) technology assessment is performed within institutional processes with the participation of independent experts and takes into consideration the feasibility of the NBS programme with respect to local conditions (e.g.: availability of infrastructure, medical professionals with expertise in screened diseases' diagnosis and treatment and the organisation of the entire chain of health care), assessed according to criteria defined at EU level within the overall framework. More technical definitions might be provided by the EU-level technology assessment.

c. National decision-making

The decision-making step remains at the national/regional level and is separate from the national technology assessment process. The decisions made and the ways in which the technology assessments have been taken into consideration are to be documented and made public.

This structured framework could result, at national level, in a decision making process centred on the improvement of health, reduced burden of the preliminary scientific assessment, and in increased trust in the health systems for patients, their advocates and citizens in general, while considering the health system sustainability and the health priorities of a country. From an EU perspective, it will provide better consistency in the services offered by different countries and a flexible process, able to take into account the technological progress.

2. Legal basis and informed consent

A national legal basis for the operation of neonatal screening programmes, which can be tailored to local conditions within a common framework, would be important to ensure the necessary quality to the system. It would ensure the rights of infants to healthcare with an offer of NBS, which is defined through a shared procedure and transparent assessment.

Legal bases mandating participation in neonatal screening programmes might limit the burden of asking and archiving the informed consent; however the mandatory nature of NBS should be accompanied with provisions for adequate and transparent information to parents and public, as well as with an opt-out system, allowing parents to refuse the service.

The national legal basis might furthermore regulate consistently the following issues:

- the storage and the delayed use of samples and the associated consent;
- the identification of eligible benefits;
- the communication of results to parents and/or patients, including unintended findings;
- the collection and communication of data for the assessment of the programme and for improving the knowledge on disease and treatment;
- ensure quality control and and quality assurance
- sustain funding.

An EU action can help promote the extension of quality control and assurance processes, and define criteria of quality and of the operation of quality assessment, thus ensuring the achievement of health care quality targets, without dictating practical and technical arrangements of the national neonatal screening systems. Exchange of expertise might be key. Indeed, at present, the performance of the screening laboratory procedures in EU can hardly be assessed since studies are occasional and data are rarely known. Accreditation and certification procedures take place in about half of the countries, with a variety of standards. It is true, however, that most, if not all, screening laboratories participate in External Quality Assessment programmes. Other steps of the NBS system participate less frequently in quality control procedures. Use of guidelines and application of quality control and quality assurance programmes have to be more extensively used in a number of steps of the NBS process.

3. Training of professionals

While any assessment of the skills of laboratory screening professionals and of medical professionals is outside the scope of this work and is not addressed here, the survey indicated that professional training needs to be improved and extended on specific aspects especially relevant for NBS, such as communication with parents at all steps of the NBS process, from the pre-natal steps to the education of parents confronted with positive screening result. Appropriate training may effectively contribute to improvements necessary in specific steps of the process, which are highlighted separately.

4. Networking of specialists, screening laboratories and centres of expertise

Already part of the recommendations for an action in the field of rare diseases, networking of centres of expertise and of specialists, may speed up consultation and confirmation of individual diagnosis, as well as facilitate debate and consensus on the best strategies for confirmatory investigations and treatment, and allow easier access to quality care in countries with less expertise on selected diseases. Cooperation may help smaller jurisdictions to perform laboratory screening and confirmatory diagnosis at a reasonable cost. Good practices may serve to improve expertise in teams elsewhere.

5. Communication of screening results to parents

Availability of written material, at the time of first communication to parents of the meaning and the consequences of the positive outcome of NBS, can be regarded as particularly important, since it can support parents' understanding of and coping with the diagnosis of the chronic disorder in their children. However, printed and/or digital material is available in more than 50% screening countries for few diseases only.

Communication of a positive screening result and confirmed diagnosis could be better regulated with the aim of ensuring information which is more suitable to parents and families as well as reducing their anxiety.

6. Parents' and patients' empowerment after diagnosis

Only half of the respondents (49%) reported to have a guideline or directive regulating the involvement of professions in the treatment of patients with disorders they screen for. Written and/or digital material explaining treatment to parents is not always available. Better parents' and patients' empowerment may improve the management of care, reduce the burden of care for the public health system and improve the patients' and familys' quality of life. Patients' and parents' organisations may play a role in assuring optimal quality of care for their infants' disorder and in providing respite initiatives for the family carer.

Along the lines of the EU Recommendation for an action on rare diseases and the EUROPLAN documents, an EU policy may facilitate sharing documents and experiences for the benefit of countries which have not the material available yet, as well as to promote the involvement of parents' and patients' associations.

7. NBS programme assessment and epidemiological evaluation

Communication of long-term clinical outcomes to the different actors in the NBS system (including screening laboratory) and to a central registry will make the evaluation of the screening programmes and research on optimal treatment of the screened diseases possible.

Although treatments are, overall, started within the recommended age in practically all countries, there are some diseases where a rather high number of patients are already symptomatic at the start of treatment. At the same time there is wide variability among countries in the timing of each step of the NBS process preceding the start of treatment. Registries could help to evaluate the consequences of different approaches.

Important synergies may result if the initiatives of data collection at local levels would be harmonised and cross-linked to allow the establishment of national and international networks and registries for the NBS programme assessment and for clinical and epidemiological purposes.

8. Economic evaluation

Epidemiological evidence of effective prevention and cost-effectiveness are the main reasons to implement a screening programme for a certain disorder. Moreover, information on the cost-effectiveness of a program is of main importance for countries to plan and evaluate public health services. However, systematic and economic analysis is very rare and is extremely difficult, especially for small population countries.

Therefore, there is a need for an action, which, in association with the initiatives devoted to the assessment of economic dimensions of NBS programmes, allows the recording and comparability of key data on NBS costs and outcomes.

C.6 General recommendations for genetic counselling - EuroGenTest

http://www.eurogentest.org/web/files/public/unit3/guidelines%20of%20GC%20final.pdf

[…]

6. General recommendation for genetic counselling

- Genetic counselling should be regarded as an integral part of the genetic testing process. Genetic counselling cannot be compulsory; medical acts are very exceptionally compulsory. It should, however, be offered and strongly recommended in most testing situations as explained above. If an individual insists on having a test without genetic counselling, the medical facts and possible consequences should be discussed by the clinician ordering the test. In these situations, non-genetics health care professionals have a responsibility to recognize their abilities and limitations with regard to provision of genetic services. Furthermore, both genetics and non-genetics health care professionals should not agree to testing without pre-test counselling in circumstances where doing so would go against their professional judgement. According to good clinical practice, predictive tests for future severe illnesses with no options for treatment or prevention should not be performed without pre- and post-test genetic counselling, psychosocial evaluation and follow-up.
- Genetic counselling has to be provided or supervised by a health-care professional appropriately trained for genetic counselling.
- Genetic counselling should be given in a language well understood by the individual. When this is not possible, options such as using an interpreter should be offered.
- Before actual testing takes place, there should be free and informed consent. In situations where testing children or other persons who are not able to give informed consent is considered, those individuals should be involved in genetic counselling and in the decision-making process, according to their capacities. Adequate authorisation for genetic testing of children or persons who are not able to give informed consent is required from their parents or legal representatives. Testing for adult onset conditions in children should only be considered when treatment or surveillance would begin in childhood.
- If the counsellee decides to proceed for the test, a description of the circumstances associated with the test should be sent, together with the sample, to the testing laboratory as the interpretation of the results depends on the context.
- The resources needed to perform genetic tests and to provide the appropriate pre- and post-test counselling should be developed and put in place simultaneously.

Pre-test genetic counselling

1. In pre-test genetic counselling individuals are informed about the purpose of the test, including up-to-date, reliable description about symptoms and natural history of the disease, prospects of prevention or early diagnosis and treatment, inheritance pattern, the risk of disease in the counsellee's situation, available reproductive choices, reliability and limitations of the test concerned, and possible psychological impact and other consequences of the test result to the counsellee and his/her family/relatives. Privacy and confidentiality of the results, as well as possible consequences related to its disclosure to third parties, such as insurance companies and employers, are discussed, when appropriate. The counsellor is not coercive in any way; this principle is also explained to the counsellee.
2. Pre-test counselling includes discussion about the rights to know and to decide including the right not-to-know.
3. Possible uncertainties due to present lack of knowledge are declared discussion about the need to inform relatives about the test result, as well as the best ways to do this, are initiated, especially in conditions where early diagnosis may improve the prognosis.
4. Depending on the resources available, as well as the context and the disease being tested, further genetic counselling sessions or consultation with a psychologist should be offered. The possibility of contact with a social worker and/or patient /lay support organisations should also be offered, where applicable.
5. Written materials and/or reliable Internet addresses related to the subject should be offered when available.
6. The counsellor should offer assistance in decision making, and encourage the counsellee to take ample time for it, whenever possible.
7. A written summary of the discussion should be prepared, if the counsellee so wishes.

Post-test genetic counselling

1. After disclosure of test results, the first focus is on the emotional impact on counsellee and others involved. Depending on the resources available, as well as the context and the disease being tested, follow-up contacts with the genetic counselling unit should be offered, and/or a consultation with a psychologist. The possibility to contact a social worker and patient/lay support organisations should also be offered. A written summary of the test result and issues discussed during the counselling should be, as a rule, given to the counsellee.
2. Points 1) and 2) from pre-test genetic counselling may have to be repeated.
3. Implications to the individual (including a follow-up plan, when relevant) and his/her near relatives should be discussed
4. A strategy to inform relatives has to be discussed with the counsellee (or, if necessary, a decision to discuss this further, after time for reflection).
5. Written material to help the counsellee to spread the information in the family may also be offered.

C.7 "Cross Border Heath Care Directive" – DIRECTIVE 2011/24/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 9 March 2011 on the application of patients' rights in cross-border healthcare

http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF

NB The text of the Directive is not reported below in full. Only the following two articles are provided herewith: ERNs (Article 12) and Rare Diseases (Article 13).
The full text is available online at the weblink provided above.

However, relevant provisions for RD patients and the application of their rights to healthcare in other EU countries are provided throughout the full text of the Directive. Therefore, in order to facilitate the task, please find below the Structure of the Directive with all its chapters.

Additionally, to ease understanding and reading of the Directive, please find herewith weblink to essential Q&A documents developed respectively by EURORDIS and the European Commission:

- EURORDIS Q&A on Cross-border Healthcare Directive: http://e-news.s3.amazonaws.com/Q%26A_cross_border_care_final-1.pdf
- European Commission - Q&A on Patients' Rights in Cross Border Healthcare: http://europa.eu/rapid/press-release_MEMO-11-32_en.htm?locale=en

Código de campo alterado

Structure of the DIRECTIVE 2011/24/EU on the application of patients' rights in cross-border healthcare

Article 12 - European reference networks

1. The Commission shall support Member States in the development of European reference networks between healthcare providers and centres of expertise in the Member States, in particular in the area of rare diseases. The networks shall be based on voluntary participation by its members, which shall participate and contribute to the networks' activities in accordance with the legislation of the Member State where the members are established and shall at all times be open to new healthcare providers which might wish to join them, provided that such healthcare providers fulfil all the required conditions and criteria referred to in paragraph 4.

2. European reference networks shall have at least three of the following objectives:

(a) to help realise the potential of European cooperation regarding highly specialised healthcare for patients and for healthcare systems by exploiting innovations in medical science and health technologies;EN 4.4.2011 Official Journal of the European Union L 88/61

(b) to contribute to the pooling of knowledge regarding sickness prevention;

(c) to facilitate improvements in diagnosis and the delivery of high-quality, accessible and cost-effective healthcare for all patients with a medical condition requiring a particular concentration of expertise in medical domains where expertise is rare;

(d) to maximise the cost-effective use of resources by concentrating them where appropriate;

(e) to reinforce research, epidemiological surveillance like registries and provide training for health professionals;

(f) to facilitate mobility of expertise, virtually or physically, and to develop, share and spread information, knowledge and best practice and to foster developments of the diagnosis and treatment of rare diseases, within and outside the networks;

(g) to encourage the development of quality and safety benchmarks and to help develop and spread best practice within and outside the network;

(h) to help Member States with an insufficient number of patients with a particular medical condition or lacking technology or expertise to provide highly specialised services of high quality.

3. Member States are encouraged to facilitate the development of the European reference networks:

(a) by connecting appropriate healthcare providers and centres of expertise throughout their national territory and ensuring the dissemination of information towards appropriate healthcare providers and centres of expertise throughout their national territory;

(b) by fostering the participation of healthcare providers and centres of expertise in the European reference networks.

4. For the purposes of paragraph 1, the Commission shall:

(a) adopt a list of specific criteria and conditions that the European reference networks must fulfil and the conditions and criteria required from healthcare providers wishing to join the European reference network. These criteria and conditions shall ensure, inter alia, that European reference networks:

(i) have knowledge and expertise to diagnose, follow-up and manage patients with evidence of good outcomes, as far as applicable;

(ii) follow a multi-disciplinary approach;

(iii) offer a high level of expertise and have the capacity to produce good practice guidelines and to implement outcome measures and quality control;

(iv) make a contribution to research;

(v) organise teaching and training activities; and

(vi) collaborate closely with other centres of expertise and networks at national and international level;

(b) develop and publish criteria for establishing and evaluating European reference networks;

(c) facilitate the exchange of information and expertise in relation to the establishment of European reference networks and their evaluation.

5. The Commission shall adopt the measures referred to in paragraph 4(a) by means of delegated acts in accordance with Article 17 and subject to the conditions of Articles 18 and 19. The measures referred to in points (b) and (c) of paragraph 4 shall be adopted in accordance with the regulatory procedure referred to in Article 16(2).

6. Measures adopted pursuant to this Article shall not harmonise any laws or regulations of the Member States and shall fully respect the responsibilities of the Member States for the organisation and delivery of health services and medical care.

Article 13 - Rare diseases

The Commission shall support Member States in cooperating in the development of diagnosis and treatment capacity in particular by aiming to:

6. (a) make health professionals aware of the tools available to them at Union level to assist them in the correct diagnosis of rare diseases, in particular the Orphanet database, and the European reference networks;
7. (b) make patients, health professionals and those bodies responsible for the funding of healthcare aware of the possibilities offered by Regulation (EC) No 883/2004 for referral of patients with rare diseases to other Member States even for diagnosis and treatments which are not available in the Member State of affiliation.